Incannex Healthcare (IXHL) Q3 2026 earnings summary

Executive summary

• Focused on developing combination therapies for chronic conditions, with lead programs IHL-42X (obstructive sleep apnea), PSX-001 (generalized anxiety disorder), and IHL-675A (rheumatoid arthritis), all in Phase 2 clinical development or beyond.

• Completed a 1-for-30 reverse stock split in February 2026 and executed a $10 million registered direct offering in March 2026.

Financial highlights

• Cash and cash equivalents rose to $74.5 million as of March 31, 2026, up from $15.0 million at June 30, 2025.

• Net loss for the nine months ended March 31, 2026 was $16.8 million, compared to $15.3 million for the same period in 2025.

• Total comprehensive loss for the nine months ended March 31, 2026 was $17.3 million.

• Operating expenses for the nine months ended March 31, 2026 were $17.8 million, up from $16.3 million year-over-year.

• No revenue generated in the period; R&D tax incentive income decreased to $1.0 million from $2.2 million year-over-year.

Outlook and guidance

• Sufficient cash resources to fund planned operations and capital expenditures for at least twelve months from the reporting date.

• Expects research and development and general and administrative expenses to increase as clinical programs advance.

• Plans to continue funding through equity offerings, debt, and strategic collaborations until product revenues are realized.